Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Projected to Strengthen in Value and Scale by 2029
Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Estimated Market Size and CAGR of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market for the Period 2025–2029?
The poly (adp-ribose) polymerase (parp) inhibitors market size has grown rapidly in recent years. It will grow from $6.53 billion in 2024 to $7.49 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to increasing cancer incidence, increasing genetic testing, increasing success in clinical trials, growing insurance coverage, and growth in cancer research.
The poly (adp-ribose) polymerase (parp) inhibitors market size is expected to see rapid growth in the next few years. It will grow to " $13.15 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to the rising production and supply of drugs, the growing prevalence of BRCA-mutated cancers, the rising prevalence of breast cancer, the growing use of monoclonal antibodies, and the rising healthcare expenditure. Major trends in the forecast period include advancements in biomarker research, combination therapies, integration of artificial intelligence in drug development, advancements in biomarker-driven therapy, and development of next-generation PARP inhibitors.
Get your free report sample today:
Which Primary Drivers Are Expected to Shape the Future of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The rising prevalence of breast cancer is expected to propel the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market going forward. Breast cancer refers to a disease in which cells in the breast grow uncontrollably, forming a malignant tumor that can spread to other parts of the body. The rising prevalence of breast cancer is attributed to factors such as aging populations, lifestyle changes, genetic predisposition, hormonal imbalances, obesity, alcohol consumption, and increasing exposure to environmental risk factors. PARP inhibitors help breast cancer patients by blocking the PARP enzyme's ability to repair DNA damage in cancer cells, leading to cell death, particularly in tumors with BRCA1 or BRCA2 mutations. For instance, in January 2025, according to the National Breast Cancer Foundation, a US-based organization, one in every eight women in the United States will be diagnosed with breast cancer during her lifetime. In 2024, 310,720 women and 2,800 men were diagnosed with invasive breast cancer. Therefore, the rising prevalence of breast cancer is driving the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market.
Which Segments Are Likely to Shape the Future Outlook of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The poly (adp-ribose) polymerase (parp) inhibitorsmarket covered in this report is segmented –
1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types
2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy
2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer
3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer
4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations
Which Emerging Trends Are Shaping the Future of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are focusing on developing advanced cancer treatments, such as anticancer medicines, to target specific genetic mutations prevalent in certain cancers. Anticancer medicines are drugs used to treat cancer by inhibiting the growth of cancer cells, preventing their spread, or destroying them. These medicines work through various mechanisms, including interfering with cell division, blocking specific proteins essential for tumor growth, or stimulating the immune system to fight cancer. For instance, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched IBYRA, a generic version of the PARP inhibitor olaparib, in India. The drug provides an affordable and targeted treatment option for patients with HRD-positive and BRCA-positive cancers. It significantly reduces treatment costs compared to the innovator drug.
Which Firms Represent the Competitive Benchmark Within the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.
Get the detailed poly (adp-ribose) polymerase (parp) inhibitors market report today
Which Regions Are Driving the Highest Demand in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment